Nivolumab plus Ipilimumab - Combination checkpoint blockade effective in pre-surgical setting for early-stage lung cancers

Neoadjuvant, or pre-surgical, treatment with Nivolumab ( Opdivo ) plus Ipilimumab ( Yervoy ) resulted in an overall major pathologic response ( MPR ) rate of 33% of treated patients with early-stage, resectable non-small cell lung cancers, meaning these patients had less than or equal to 10% viable tumor remaining at surgery.
With these results, the combination immunotherapy met the pre-specified trial efficacy endpoint of the phase II NEOSTAR trial conducted by researchers at The University of Texas MD Anderson Cancer Center.

The trial arm testing Nivolumab alone in the treated population of patients achieved a 17% MPR rate, for an overall MPR rate across both trial arms of 25%.

The results of the trial were presented at the 2019 American Society of Clinical Oncology ( ASCO ) Annual Meeting.

Patients with early-stage or locally advanced lung cancer have the potential to be cured of their disease, but more than half of those patients will have a recurrence if treated with surgery alone.
Therefore, there is an urgent need to identify the most effective neoadjuvant therapy options to reduce the risk of relapse.

Preclinical studies in mice revealed that increased expression of PD-L1, an immune checkpoint protein, in lung adenocarcinoma tumors is critical for the development and survival of metastases, providing the rationale for testing immunotherapy in the neoadjuvant setting.

Prior to this study, researchers knew that single agent neoadjuvant immunotherapy has achieved a MPR rate of 22 to 45%, but the combination of anti-PD-1 and anti-CTLA-4 immune checkpoint blockade before surgery in resectable NSCLC patients had not yet been tested.
In mouse models of resectable and spontaneously metastatic non-small cell lung cancer, the combination of immunotherapy prior to surgery was superior to adjuvant combined therapy in prolonging survival and reducing the frequency of lung metastases, supporting further investigation of neoadjuvant combined immune checkpoint blockade in the clinical setting.

The researchers designed the trial to test the effectiveness of combination immune checkpoint inhibitors priory to surgery.
The trial enrolled 44 patients who were randomized to receive either neoadjuvant Nivolumab ( anti-PD-1 ) alone or Nivolumab plus Ipilimumab ( anti-CTLA-4 ).

The trial's primary endpoint was MPR, hypothesized to be higher for single and/or combination immune checkpoint inhibitors compared to the rate induced by historical neoadjuvant chemotherapy controls.
The pre-specified trial efficacy endpoint for a specific treatment to be considered promising was greater than or equal to six MPRs in the intent to treat population.

MPR has been adopted as a surrogate endpoint in neoadjuvant trials for patients with resectable non-small cell lung cancer patients, as it has been shown to positively correlate with improved overall and recurrence-free survival outcomes.

Seven out of 21 patients treated pre-operatively with the combination therapy achieved an MPR, and four of 23 patients treated with Nivolumab alone achieved an MPR.

Although the trial was not powered to make a comparison between the two arms, the combination therapy appeared more effective at reducing viable tumor at surgery.
Six patients ( 38% ) that received the combination therapy and underwent surgery on trial achieved a complete pathological response, or tumor disappearance at resection, compared to just two patients ( 10% ) receiving Nivolumab alone.
Also, the majority of patients with more than 50% viable tumor remaining at surgical resection received single-agent Nivolumab therapy.

The treatments were generally well-tolerated, with no unacceptable toxicity or increased perioperative morbidity and/or mortality noted; however, careful perioperative monitoring is advised with these agents.

The trial also collected a variety of biospecimens from patients before, during and after treatment, which enabled researchers to investigate why results vary from patient to patient and understand the dynamic changes induced by therapy in potential biomarkers.
They discovered that elevated tumor expression of the immune checkpoint protein PD-L1 prior to therapy was positively correlated with radiographic responses and with pathologic tumor regression at surgery.

Preliminary immunologic characterization of resected tumors from patients treated with immunotherapy has indicated that the combination therapy is associated with an increased number of tumor-infiltrating lymphocytes as compared to monotherapy, and that some of these T cells might have tumor reactive activity.

There are limitations to this trial, as it was overall a small cohort. ( Xagena )

Source: University of Texas MD Anderson Cancer Center, 2019



Altri articoli

TAPUR ( Targeted Agent and Profiling Utilization Registry ) is a phase II basket study evaluating anti-tumor activity of targeted...

In the ongoing, multicohort, phase 2 GEOMETRY mono-1 study, Capmatinib ( Tabrecta ) has shown efficacy in METex14–mutated non–small cell...

Osimertinib ( Tagrisso ) is a 3rd-generation, CNS-active, epidermal growth factor receptor ( EGFR ) tyrosine kinase inhibitor ( TKI...

In Part 1 of the phase II CheckMate 568 study, Nivolumab ( Opdivo ) plus Ipilimumab ( Yervoy ) was...

As part of an ongoing phase Ib/II study ( NCT02501096 ) in patients with selected solid tumors, Lenvatinib [ Lenvima...

Camrelizumab is a fully humanized, monoclonal antibody against PD-1. A study has assessed the efficacy and safety of Camrelizumab plus...

Abemaciclib ( Verzenio ) in combination with standard adjuvant endocrine therapy has met the primary endpoint of invasive disease-free...

Tthe phase III IPATential150 study met its co-primary endpoint of radiographic progression-free survival ( rPFS ) in patients with metastatic...

The FDA ( U.S. Food and Drug Administration ) has approved Tecentriq ( Atezolizumab ) in combination with Avastin (...